HUTCHMED (China) Ltd (H7T2.BE)
| Previous close | 3.6400 |
| Open | 3.6200 |
| Bid | 3.3800 x N/A |
| Ask | 3.7400 x N/A |
| Day's range | 3.5000 - 3.6400 |
| 52-week range | 1.9900 - 3.8800 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/NYSE:TAK) received notification that the Com
Simply Wall St.HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years
It is a pleasure to report that the HUTCHMED (China) Limited ( LON:HCM ) is up 35% in the last quarter. But over the...
- GlobeNewswire
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California. Initial preclinical data will be presented for HMPL-506, a novel, highly potent and d
